AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Amneal Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$19.36+0.18 (+0.94%)

Close on Oct 19, 2026

Market cap: $6.35B
P/E (TTM): 39.5
Dividend yield: –

Amneal Pharmaceuticals, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Stock-Based Compensation	32	28	27	32	28	21	22	168	0	0
Deferred Income Taxes	0	0	0	0	0	0	372	-9.44	0.74	0.12
Other Non-Cash Items	-4.73	-1.52	-9.92	-8.83	-5.63	-12	-7.31	1.87	-9.94	-0.20
Change in Accounts Receivable	-121	-163	126	-80	-24	17	-133	89	35	-122
Change in Inventory	-87	-131	-126	-102	-49	-114	-20	-42	-32	-43
Change in Accounts Payable	21	235	-94	110	-44	0.31	-10	-54	18	6.27
Operating Cash Flow	340	295	346	65	242	379	1.71	250	234	115
Capital Expenditures	-70	-52	-43	-46	-48	-56	-47	-83	-95	-123
Acquisitions	–	0	0	-85	-147	-251	0	-325	0	0
Sale of Property, Plant & Equipment	–	–	–	–	–	0	0	25	0	0
Divestitures	–	–	–	–	0	0	35	0	16	0
Investing Cash Flow	-112	-63	-69	-174	-194	-318	-20	-396	-99	-125
Dividends Paid	–	–	–	–	–	0	0	-183	-375	-201
Share Repurchases	–	–	–	–	–	–	–	–	–	-0.01
Debt Issued	2,695	0	218	0	0	–	–	–	–	–
Taxes Paid on Share-Based Awards	-22	-7.95	-2.38	-3.57	-2.66	-0.86	-0.93	0	0	–
Financing Cash Flow	-32	-212	-213	-107	-138	132	-46	288	-95	-19
Foreign Exchange Rate Adjustments	-1.68	-1.00	0.07	-5.68	0.10	1.04	-2.25	-0.67	-0.24	1.48
Net Change in Cash	195	19	64	-222	-90	194	-66	141	40	-28
Free Cash Flow	270	243	302	19	194	323	-45	167	139	-7.70
Income Taxes Paid	21	15	2.50	13	-16	100	10	35	-5.78	4.92
Interest Paid	198	264	193	143	122	130	159	132	65	51

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 39.3%
Operating margin: 14.6%
Net margin: 5.0%
Return on equity, FY2025: -80.0%

Financial strength

Current ratio: 2.20
Debt to equity: 77.83
Debt to assets: 68.1%
Cash to current liabilities: 14.5%

Valuation

P/E ratio: 39.5
Price to sales: 2.04
Price to book: 192.35
Dividend yield: –